FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
Second clinical program entering Phase 2 with data expected 2026BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest ...
Tempest Therapeutics received ‘Study May Proceed’ letter from FDA on TPST-1495
Tempest Therapeutics (TPST) announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the U.S.
Nasdaq11d
Tempest Therapeutics Receives FDA Clearance For Phase 2 Trial Of TPST-1495 In FAP
a novel dual receptor inhibitor of prostaglandin or PGE2 signaling, for the treatment of Familial Adenomatous Polyposis or FAP. The clearance follows the successful submission of the IND ...
University of Bristol7y
CTB group
Furthermore, COX-2-derived PGE2 promotes cell proliferation at least in part via the stimulation of β-catenin/TCF-4 activity, as well as via enhancement of Ras-MAPK signalling. During hypoxia, ...
The Bakersfield Californian11d
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of ...
Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the ...
Morningstar11d
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
the company’s novel dual receptor inhibitor of prostaglandin (PGE2) signaling, in a Phase 2 clinical trial for the treatment of patients with Familial Adenomatous Polyposis (FAP). “Receiving ...